TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Verrica Pharmaceuticals ( (VRCA) ) has shared an announcement.
On November 23, 2025, Verrica Pharmaceuticals announced a private placement financing agreement to raise approximately $50 million. This funding will be used to retire the company’s debt facility with OrbiMed, extend its cash runway into mid-2027, and support further development of its product pipeline, including the advancement of YCANTH and VP-315. The financing, expected to close on November 25, 2025, involves selling shares and warrants to institutional and accredited investors, with Caligan Partners gaining rights to appoint a board member. This strategic move aims to solidify Verrica’s financial position and enhance its market presence in dermatology therapeutics.
The most recent analyst rating on (VRCA) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.
Spark’s Take on VRCA Stock
According to Spark, TipRanks’ AI Analyst, VRCA is a Neutral.
Verrica Pharmaceuticals’ overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and negative equity. While the earnings call provided some positive developments, such as growth in YCANTH dispensations and strategic partnerships, these are overshadowed by the company’s financial instability. Technical analysis suggests a bearish trend, and the valuation metrics are unattractive due to the negative P/E ratio.
To see Spark’s full report on VRCA stock, click here.
More about Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases requiring medical interventions. Its flagship product, YCANTH, is the first FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting millions in the U.S., primarily children. The company is also working on treatments for common warts and non-melanoma skin cancers.
Average Trading Volume: 289,438
Technical Sentiment Signal: Sell
Current Market Cap: $39.95M
See more data about VRCA stock on TipRanks’ Stock Analysis page.